Immunotherapy (PD-1 Inhibitors e.g., Pembrolizumab/Nivolumab)
Treatment used for 1 condition
Total Trials
20
Total Participants
1K
Avg Effectiveness
40%
Avg Safety Score
60%
Conditions Treated
Click on a condition to view detailed treatment information and clinical trial data.